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Revertant mosaicism is an infrequently observed phenomenon caused by spontaneous correction of a pathogenic allele. We have
observed such reversions caused by mitotic recombination of mutant TERC (telomerase RNA component) alleles in six patients from
four families affected by dyskeratosis congenita (DC). DC is a multisystem disorder characterized by mucocutaneous abnormalities,
dystrophic nails, bone-marrow failure, lung fibrosis, liver cirrhosis, and cancer. We identified a 4 nt deletion in TERC in a family with
an autosomal-dominant form of DC. In two affected brothers without bone-marrow failure, sequence analysis revealed pronounced
overrepresentation of the wild-type allele in blood cells, whereas no such skewing was observed in the other tissues tested. These obser-
vations suggest that this mosaic pattern might have resulted from somatic reversion of the mutated allele to the normal allele in blood-
forming cells. SNP-microarray analysis on blood DNA from the two brothers indeed showed independent events of acquired segmental
isodisomy of chromosome 3q, including TERC, indicating that the reversions must have resulted from mitotic recombination events.
Subsequently, after developing a highly sensitive method of detecting mosaic homozygosity, we have found four additional cases
with a mosaic-reversion pattern in blood cells; these four cases are part of a cohort of 17 individuals with germline TERC mutations.
This shows that revertantmosaicism is a recurrent event in DC. This finding has important implications for improving diagnostic testing
and understanding the variable phenotype of DC.Introduction
Dyskeratosis congenita (DC [MIM 127550]) is a multi-
system bone-marrow-failure syndrome that was initially
described as a combination of nail dystrophy, abnormal
skin pigmentation, and oral leukoplakia. Affected per-
sons exhibit a susceptibility to aplastic anemia, lung
fibrosis, liver cirrhosis, and cancer.1 The clinical presenta-
tion of patients is highly variable both between and
within families.
Compared to age-matched controls, persons with DC
have abnormally short telomeres.2 Telomeres are complex
DNA-protein structures at the end of chromosomes, and
they protect the chromosomes from damage and, thereby,
maintain chromosome stability.3 Telomeres shorten with
each cell division and ultimately activate a DNA-damage
response that leads to apoptosis or cell-cycle arrest.4 In hu-
mans, telomerase-based telomere elongation is the major
mechanism that counteracts this process of telomere
shortening.5 After birth, telomerase activity is restricted
to germ cells, some stem cells and their immediate
progeny, activated T cells, andmonocytes.6 Approximately
half of the DC patients have mutations in one of six
genes that encode components of either the telomerase
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[MIM 606470]) or the telomere shelterin complex (TINF2
[MIM 604319]). Mutations in these genes result in failure
to maintain telomere length, and they primarily affect
tissues that turn over most rapidly, including bone
marrow, skin, and nails.
Individuals with DC display considerable variability in
clinical severity, which might be partly explained by geno-
type-phenotype correlations. In general, individuals with
DKC1 and TINF2 mutations exhibit an earlier and more
severe presentation than do individuals with a mutation
in one of the other genes.1,7 This finding was recently
confirmed by studies in iPS cells; such studies showed
that DKC1 mutations result in a more severe telomere-
maintenance defect than do mutations in TERT.8 Variable
clinical phenotypes are also observed among individuals
with mutations in similar DC-associated genes or even
between carriers within affected families. The disease
might even present as isolated aplastic anemia or idio-
pathic pulmonary fibrosis.9–12 In autosomal-dominant
DC, disease anticipation is one of the factors underlying
variable expression, i.e., when phenotypes are present
earlier and more severely in successive generations.13,14 A
sustained decrease in telomere length through generations
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Table 1. Clinical Features of the Dutch Family Members Affected by Dyskeratosis Congenita
II:1 II:3 II:6 II:7 III:6 III:7 III:12
Reticular pigmentation - þ ? þ - - þ
Dystrophic nails þ þ ? þ - þ þ
Leukoplakia - - ? - - - -
Bone-marrow failure - - - - thr þ (34 years) þ (15 years)
Pulmonary fibrosis þ (57 years) þ (58 years) þ (53 years) þ (57 years) - þ (33 years) þ (17 years)
Liver cirrhosis - - - - þ (21 years) - -
Osteoporosis þ (57 years) þ (65 years) ? ? þ
Malignancy - þ (66 years)a - - - - -
Age at death (years) 59 66 55 59 32 alive 26
The presence (þ) or absence (-) of each feature is reported for each individual. Age at first presentation is indicated where known. The following abbreviations are
used: thr, thrombocytopenia; ?, data not available.
aSquamous cell cancer of the head and neck region.Phenotypic expression of an inheritedmutation can also
be influenced by a mosaic tissue distribution caused by its
reversion to a normal allele. This phenomenon is infre-
quently observed andmight be recognized if a person pres-
ents with a milder-than-expected clinical course or with
a mixture of phenotypically normal and abnormal
cells.15 Mechanisms that might explain reversion include
mitotic gene conversion, back mutation, intragenic
mitotic recombination, and the occurrence of compensa-
tory mutations. Here, we report on revertant somatic
mosaicism resulting from mitotic recombination in six
DC-affected persons carrying germline TERC mutations.Subjects and Methods
Subjects and DNA Samples
All persons or their legal representatives provided informed
consent for the DNA studies and the collection of clinical data.
The studies were performed according to the guidelines of the
local ethical committees. Clinical information of the seven indi-
viduals from the Dutch family was obtained through clinical
investigation in the departments of Human Genetics and Pulmo-
nology (by authors M.C.J.J. and Y.H., respectively) of the Radboud
University Nijmegen Medical Centre and by chart review. DNA
was isolated from peripheral blood cells, frozen liver and lung
tissue, and cultured fibroblasts via standard procedures.
To screen for additional examples of reversion in TERC, we
selected subjects from the DC registry, which is located at the
Royal London Hospital and administered by Dr. Dokal. In this
study, we included 17 individuals who had a germline TERCmuta-
tion, who did not develop bone-marrow failure, and who thus did
not undergo an allogeneic stem-cell transplantation (Tables 1 and
2 and Table S1, available online).
Mutation Screening
We screened TERC and TERT for mutations by denaturing high-
performance liquid chromatography and by using direct sequence
analysis with the primers and PCR conditions previously
described.16,17 All mutations in TERC are numbered accordingThe Ameto the reference sequence with RefSeq accession number
NR_001566.1.Genome-Wide SNP Genotyping
DNA samples were hybridized on a SNP 6.0 array according to the
manufacturer’s (Affymetrix, Santa Clara, CA, USA) protocols.
Copy-number and allele-specific genotyping analyses were per-
formed with the Affymetrix Genotyping Console v2.1 software
and Nexus Copy Number 5.0 software, respectively (BioDiscovery,
El Segundo, CA, USA).Sorting of Blood-Cell Lineages
Peripheral-blood mononuclear cells (PBMCs) were isolated by
Ficoll-Paque 1077 (GE Healthcare, Buckinghamshire, UK) density
gradient centrifugation (200, RT, 700 g, without brakes). The gran-
ulocytes were harvested from the flow through and kept on ice
until DNA isolation. We further purified the fraction monocytes
from the PBMCs by adhering them to a plastic surface for one
hour in a CO2 incubator and directly lysing them in QIAamp lysis-
buffer (QIAGEN, Hilden, Germany). T and B cells were purified by
means of direct cell labeling with CD3- and CD19- magnetic
beads, respectively, according to the manufacturer’s (Miltenyi Bio-
tec GmbH) protocol, and they were also kept on ice until DNA
isolation.Mosaic Homozygosity Reporter
We developed a method of identifying mosaic homozygosity by
detecting allelic imbalance in telomeric regions. This method
assesses significant shifts in the allele-contrast signal of heterozy-
gous SNPs obtained from Affymetrix SNP 6.0 arrays. The heterozy-
gous range (0–0.5) of the absolute allele contrast (from now on
referred to as the heterozygous allele contrast [HAC]) of the 3q te-
lomeric region is compared with other telomeric regions of similar
length. The length was taken as the number of SNPs on the SNP
6.0 array from TERC to the end of 3q.
We tested differences in HAC values between the 3q telomeric
region and 34 telomeric regions elsewhere on the genome by per-
forming a Wilcoxon rank test. We took the mean of the p values
and, to correct for multiple testing, multiplied this number by
the amount of telomeric comparisons (n ¼ 34). All telomericrican Journal of Human Genetics 90, 426–433, March 9, 2012 427
Table 2. TERC Mutation Carriers and Somatic Reversion
Family
Subjects
with DCa Gender
TERC
Mutation Reference
Age at
Molecular
Diagnosis
(Years)
Percentage of
Overrepresented
WT Peaksb
Reversion
Visible in
Array Plot
Significance
of the Allelic
Imbalancec
1 III:12,
liver DNA
M n.54_57del - 26 86% no 1
1 II:1 M n.54_57del - 58 100% yes 5.26 3 10-97
1 II:1,
fibroblast DNA
40% NA NA
1 II:7 M n.54_57del - 57 100% yes 1.58 3 10-84
1 II:7,
lung DNA
60% NA NA
2 1 M n.96_97del Vulliamy et al. (2004)14 11 44% no 1
3 2 M n.408C>G Vulliamy et al. (2001)16 18 - no 1
4 3 M n.110_113del Vulliamy et al. (2002)11 51 42% no 1
5 4 M n.54_57del Vulliamy et al. (2006)19 53 88% no 7.91 3 10-25
5 5 F n.54_57del Vulliamy et al. (2006)19 18 36% no 0.67
6 6 F n.79del Vulliamy et al. (2006)19 77 54% no 1
5 7 F n.54_57del Vulliamy et al. (2006)19 25 88% yes 1.76 3 10-100
5 8 F n.54_57del Vulliamy et al. (2006)19 29 68% no 1
3 9 F n.408C>G Vulliamy et al. (2001)16 0 - no 1
7 10 M n.48A>G Vulliamy et al. (2006)19 54 - no 1
8 11 F n.2G>C Marrone et al. (2007)32 54 - no 1
8 12 F n.2G>C Marrone et al. (2007)32 28 - no 1
9 13 M n.176A>C Vulliamy et al. (2011)33 5 - no 1
10 14 M n.110_113del Vulliamy et al. (2011)33 54 76% no 2.75 3 10-11
11 15 F n.95_96del Vulliamy et al. (2011)33 69 88% yes 3.95 3 10-49
12 16 M n.107G>T Vulliamy et al. (2011)33 55 - no 0.38
13 17 F n.36C>T Vulliamy et al. (2011)33 45 - no 1
For the bold individuals in column 2, we found significant evidence of revertant somatic mosaicism. The following abbreviations are used: WT, wild-type; M, male;
F, female; and NA, data not available.
aDNA was isolated from peripheral blood unless stated otherwise.
bPercentage of WT peaks that are higher than the correspondingmutant peak in the sequencing chromatogram. For each sample with a small deletion in TERC, 50
nonsynonymous base-pair positions (double peaks in the chromatogram) just downstream of the mutation were scored. Twenty samples with a frameshift muta-
tion in BRCA1 were scored as a control cohort, resulting in a median of 48% (scores ranging from 34% to 58%) WT peaks that are higher than the corresponding
mutant peaks.
cAs calculated by the mosaic homozygosity reporter; the formulas are described in the Subjects and Methods section and summarized in the legend of Table
S2.regions were included, except for those in which the window of
SNPs crossed the centromere or those that had no probe coverage,
i.e., 13p, 14p, 15p, 17p, 18p, 19p, 19q, 21p, and 22p. The formulas
used for this method are depicted in the legend of Table S2.Results
Family History
A Dutch family with autosomal-dominant DC (Figure 1
and Table 1) was identified through a 26-year-old proband
(III:12). This proband presented with multiple features,
i.e., dystrophic nails, reticular pigmentation of the neck
and chest, a gray lock of hair, aplastic anemia, lung fibrosis,428 The American Journal of Human Genetics 90, 426–433, March 9liver disease, and avascular necrosis of the hips, compatible
with DC. The family history was positive for lung fibrosis.
In addition, a cousin died because of liver cirrhosis, and
another cousin was recently diagnosed with aplastic
anemia.
Underrepresentation of a Mutant TERC Allele in Two
Affected Family Members
Sequence analysis of DNA derived from liver tissue of the
proband revealed no pathogenic mutation in TERT and
a heterozygous 4 bp deletion (n.54_57del) in exon 1 of
TERC (Figure 2). TERC encodes the telomerase RNA
component that serves as a template in the process of, 2012
Figure 1. Pedigree of the Dutch Family Affected by DC
The proband (III:12) is marked by an arrow.telomere elongation.18 This deletion disturbs the template
domain of TERC and is, therefore, considered to be patho-
genic. A partly overlapping deletion has previously been
reported in an individual who presented with hypoplastic
myelodysplasia and nail dystrophy at 13 years of age.19
Subsequent segregation analysis confirmed the presence
of the mutation in all affected family members. In the
father (II:7) and an uncle (II:1) of the proband, we observed
discrepancies in bidirectional sequencing-peak heights in
independent PCR amplicons from blood-cell-derived
DNAs, suggesting an underrepresentation of the mutant
TERC allele (Figure 2). This phenomenon appeared to be
limited to hematopoietic cells, given that the mutation
was present in an equimolar heterozygous state (Table 2)
in DNA derived from lung tissue from II:7 and fibroblasts
from II:1 (Figure 2). The tissue-restricted nature of this
mosaicism, combined with recurrence in at least two
family members, indicates that these events might have
resulted from a somatic reversion of the mutated allele to
a normal state.
SNP-Array Analysis Reveals Mitotic Recombination
To further explore this possibility, SNP-array analysis was
performed on DNA derived from peripheral blood cells of
the two affected brothers (II:1 and II:7). Indeed, this anal-
ysis revealed the presence of acquired uniparental disomies
(UPDs) of a large chromosome 3q segment, which
included TERC in both brothers (Figure 3). Moreover, in
person II:1, the UPD regionwas flanked by a small genomic
stretch with an intermediate level of homozygosity, sug-
gesting the presence of two subpopulations of cells with
differently sized segments of acquired UPD involving the
same parental chromatid. Therefore, we conclude that
the underrepresentation of the mutant TERC allele inThe Ameblood DNA of person II:1 was caused by at least two inde-
pendent events of mitotic recombination and that this
recombination mechanism explains the reversion in
both individuals.
Mosaic Reversion Patterns in Distinct Blood Cell
Lineages
In order to determine the origin of the two subpopulations
of cells with differently sized segments of acquired UPD, we
resequenced the TERC deletion in DNA isolated from
different blood cell lineages of person II:1 (Figure S1A).
Whereas the B cell lineage again showed a subfractional
reversion, we observed normal heterozygous levels of the
mutant allele in the T cells and an almost complete loss of
the mutated allele in the myeloid lineage (granulocytes
and monocytes). These sequencing results were reflected
in the amount of UPD observed by SNP-array analysis
(Figure S1B). Furthermore, both subpopulations exhibiting
distinct mitotic-reversion events were observed in B cells,
granulocytes, and monocytes. These data indicate that
both events of mitotic recombination must have occurred
in an early hematopoietic progenitor cell, i.e., before the
segregation of myeloid- and lymphoid-differentiation
pathways. Our finding that mitotic reversion is not visible
in the B-allele-frequency plot of the Tcells can be explained
by the remarkable longevity of T-lymphocyte subsets.20
Revertant Somatic Mosaicism in Additional
Individuals Carrying a Germline TERC Mutation
For mitotic-reversion analysis, we selected from 12 families
17 individuals with a germline TERC mutation and with
no history of bone-marrow failure (Table 2 and Table S1).
TERC was resequenced in DNA derived from peripheral
blood cells of those individuals, and SNP-array analysesrican Journal of Human Genetics 90, 426–433, March 9, 2012 429
Figure 2. Sequence Analysis of TERC
Sequence analysis of TERC revealed a heterozygous 4 bp deletion,
n.54_57del (RefSeq accession number NR_001566.1), in the
proband (III:12). The wild-type allele was observed more than
the mutated allele in DNA isolated from peripheral blood cells
from the father (II:7) and an uncle (II:1) of the proband. Analysis
of DNA from the father’s lung tissue and from the uncle’s cultured
fibroblasts revealed that the mutation was heterozygous. These
data are in concordance with somatic events in the hematopoietic
compartments of II:7 and II:1; these events resulted in loss of the
germline mutation in a considerable fraction of the peripheral
blood cells.were performed. Visual inspection of the B-allele-frequency
plot revealed the presence of mosaic homozygosity in two
cases (subjects 7 and 15; Figure 4). Subsequently, we used
a quantitative method (mosaic homozygosity reporter;
see Subjects and Methods and Table S2) to detect imbal-
ances in the intensity ratio of heterozygous SNPs, and we
identified two additional persons (subjects 4 and 14) with
significant imbalances in the allelic ratios of heterozygous
calls on the 3q arm; these imbalances are indicative of
a partial loss of the mutant allele (Table 2). Two of these
four novel subjects, a father (subject 4) and his daughter
(subject 7), are related, and they carry the same mutation
(n.54_57del) in TERC as the one observed in the Dutch
family. Subjects 14 and 15 were also affected by small
deletions n.110_113del and n.95_96del, respectively. The
sequencing chromatograms showed that directly down-
stream of the deletions in all six individuals with signifi-
cant reversion (detected by the mosaic homozygosity
reporter) there was a disparity between the peak heights
of the wild-type and the shifted mutant sequences
(Table 2). These data illustrate that mosaic reversion of430 The American Journal of Human Genetics 90, 426–433, March 9the mutant allele to the wild-type form is a recurrent event
in individuals carrying a TERC mutation.Discussion
We report reversion of a TERC mutation in six individuals
from four families affected by autosomal-dominant DC. A
mosaic pattern of somatic reversion becomes apparent
when normal cells have a selective growth advantage
over surrounding mutant cells, implying that the affected
genes are expressed in regenerating organ systems like
skin and blood.15 This holds true in particular for diseases
with an underlyingmechanism resulting in genomic insta-
bility or high mutation rates; two such diseases are Bloom
syndrome [MIM 210900] and Fanconi anemia [MIM
227650], which are both caused by gene defects in DNA-
repair pathways.21,22 Ichthyosis with confetti [MIM
609165], caused by mutations in KRT10 [MIM 148080],
is a recently described example of a skin disorder display-
ing multiple events of reversion.23 In this condition,
normal skin spots appear early in life and increase in
number and size over time. Each normal spot results from
a separate event of loss of heterozygosity on chromosome
17q, which harbors KRT10, via mitotic recombination.
Shortening of the telomeres conceivably initiates the
events of mitotic recombination in DC-affected individ-
uals. Several studies have demonstrated chromosomal
instability in DC.24–26 Telomere shortening triggers this
instability by inducing inappropriate attachment of the
chromosome ends through nonhomologous end joining
or homologous recombination pathways.27 The mitotic
recombinations on chromosome 3q might also result
from stochastic events, meaning that the reversion in DC
is mainly driven by the selective advantage of cells with
two functional copies of TERC. In this study, we have
specifically screened for additional cases of reversion
caused bymitotic recombination. Consequently, wemight
havemissed reversion events caused by othermechanisms,
including back mutation and the occurrence of compensa-
tory mutations.
Altogether, we have recorded seven different events of
reversion caused by somatic recombination in the six indi-
viduals presented here. On the basis of this observation
and given the fact that DCmeets all the criteria for a disease
that is prone to revertant mosaicism, we expect that rever-
sion will occur more often in persons affected by DC. This
creates opportunities for the identification of novel genes
associated with DC. Searching for overlapping homozy-
gous regions in DC-affected individuals who did not
develop bone-marrow failure might lead to the identifica-
tion of a causative mutation, as was previously shown for
mutations in KRT10 in Ichthyosis with confetti.23
In this study, we used several tests to identify reversion
caused by mitotic recombination. Quantitative interpreta-
tion of the SNP 6.0-array data by the mosaic homozygosity
reporter that we have developed turned out to be the most, 2012
Figure 3. Mitotic Recombination on Chromosome 3q Results in Isodisomy of TERC
B-allele frequencies (y axis) of chromosome 3 of proband III:12 (his DNA was derived from the liver), his father, II:7, and his uncle, II:1
(their DNAwas derived from peripheral blood). This analysis revealed UPD of the long arm of chromosome 3 in subject II:7. This is likely
the result of a mitotic recombination event in the centromeric region (indicated by the triangle) of chromosome 3q. In subject II:1,
mosaic UPD was observed, and two adjacent regions of chromosome 3q had different degrees of mosaicism. This suggests the presence
of two subpopulations of cells (marked as 1 and 2) resulting from independent mitotic-recombination events with different breakpoints.sensitive test. In individuals 4 and 14 (Figure 4), we did not
observe a stretch of mosaic isodisomy in the B-allele-
frequency plot, but the mosaic homozygosity reporter
revealed the presence of a significant population of cells
homozygous for a region on 3qter. Retrospectively, we
also detected that the wild-type allele was more highly rep-
resented in the sequencing chromatograms of all six
samples with a reversion event than in those with normal
heterozygosity on 3q. This latter analysis is only possible in
the case of small deletions resulting in a shifted mutant
allele because it is much more difficult to estimate the rela-
tive frequencies of two different alleles through a single
point mutation. Furthermore, an overrepresentation of
higher wild-type peaks was present in DNA isolated from
liver tissue of proband III:12; however, this could not be
confirmed by the mosaic homozygosity reporter. There-
fore, we conclude that after careful interpretation of the
sequencing chromatogram, one could suggest that a rever-
sion event is present, but performing this analysis exclu-
sively is not enough to draw firm conclusions.
All individuals with revertant somatic mosaicism in this
study carried a small deletion in TERC. One explanation
could be that these mutations are more deleterious than
missense mutations and that after correction, they result
in a greater selection advantage, which leads to revertant
mosaicism. In the literature, however, we do not find
evidence of such genotype-phenotype correlations. TimeThe Amecould be another factor influencing the chance that rever-
tant mosaicism would occur in an individual. The mean
age atmolecular diagnosis of the six persons with reversion
in our cohort is 53 years, whereas the persons without
reversion have a mean age of 34 years.
The potential presence of somatic reversion in DC has
important implications for clinical diagnostics. It is
common practice that analysis of the DC-associated genes
is performed on DNA isolated from peripheral blood cells
of a proband suspected to have DC. In case no pathogenic
mutation is found, an obvious conclusion can be that the
phenotype in the family is caused by an aberration in
a gene that has yet to be identified. On the basis of our
findings, we recommend sequence analysis on DNA ex-
tracted from other cells, such as skin fibroblasts, particu-
larly in individuals without bone-marrow failure.
Observing the reversion of a germline TERCmutation is
also important for the development of future DC therapies.
Currently, the only definitive treatment for bone-marrow
failure in DC is hematopoietic stem cell transplantation
(HSCT). The highly toxic conditioning regimens, which
are thought to be a prerequisite for donor cell engraftment,
are associated with significant adverse side effects, particu-
larly on lung and liver tissue.28–30 Dietz and colleagues re-
ported that short-term survival after HSCT in DC-affected
individuals is possible with a nonmyeloablative condi-
tioning regimen.31 Our data show that, especially in therican Journal of Human Genetics 90, 426–433, March 9, 2012 431
Figure 4. Additional DC-Affected Individuals Show Revertant Somatic Mosaicism
SNP-array analysis revealed stretches of UPD on chromosome 3q in peripheral blood DNA of subjects 7 and 15, as observed in the
B-allele-frequency plot. The starting points of these homologous stretches are indicated by a triangle. No indication of UPDwas observed
in the SNP-array data of chromosome 3q in subjects 4 and 14. However, quantitative analysis of the SNP data revealed an allelic
imbalance in these samples (Table S2), indicating the presence of a significant population of cells homozygous for a region on 3qter.
The sequence data were scored for an imbalance in peak heights between the wild-type and mutant peaks, as summarized in Table 2.
All four samples showed an overrepresentation of higher wild-type peaks.younger mononuclear cell lineages, reverted progenitor
cells have a strong selective advantage over uncorrected
cells. Therefore, isolation of autologous reverted stem cells
could probably circumvent an allogeneic stem cell trans-
plantation in a subset of individuals with DC.
In conclusion, we have observed somatic revertant
mosaicism of a germline mutation in TERC in six individ-
uals from four families affected by DC, indicating that
reversion is a recurrent event in DC. This finding is impor-
tant for improving diagnostic testing and understanding
the variable phenotype of DC. In addition, we have devel-
oped a mosaic homozygosity reporter for the interpreta-
tion of SNP-array data in the search for genomic regions
with low mosaic UPD.
Supplemental Data
Supplemental Data include one figure and two tables and can be
found with this article online at http://www.cell.com/AJHG.
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